Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
|Videos|November 1, 2013
The Role of Robotic Surgery in Gynecologic Cancer
Author(s)Mark A. Morgan, MD
Mark A. Morgan, MD, discusses the role of robotic surgery in gynecologic cancer.
Advertisement
Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses the role of robotic surgery in gynecologic cancer.
Clinical Pearls
- Based on the results of a GOG trial, it is unlikely that there is a difference in patient survival between robotic surgery and laparoscopic surgery
- Robotic surgery works better in lymph node dissections and operations on heavier patients compared to laparoscopic surgery
- The advent of robotic surgery has increased the use of minimally invasive surgery for women with endometrial or cervical cancer
Advertisement
Related to this article
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Dr Wang Highlights ESMO Lung Cancer Data Making an Impact
5